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Cellular adhesion is important during metastasis, as metastatic ells must escape From the primary site into 
tymph and blood systems, there to adhere specificalfy to sites in distant organs. We have recently selected 
monoclonal antibodies which prevent adherence of B16 mouse melanoma cells to tissue culture dishes, and 
also markedly reduce experimental lung metastasis in mice when injected before or with the tumour cells. 
Here, we investigated which step in the metastatic process may be affected by the antibodies. The possible 
inhibitory effect of antibody on tumour cell adherence to vascular endothelial monolayers and to purified 
components of the underlying extracellular matrix - fibronectin, laminin and collagen type IV - was 
studied using in vitro assays. We found that the antibodies significantly blocked attachment o laminin, 
suggesting that specific basement membrane components play an important role in attracting or otherwise 
modifying the behaviour of metastatic tumour cells. 
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I. INTRODUCTION 
Cell surfaces are crucial in all cell adhesion pro- 
cesses, and investigations with a variety of tumour 
models have indicated that cell surfaces play an im- 
portant role in metastasis as well. For instance, the 
high metastatic potential of mouse Bf6 melanoma 
subline F10 could be transferred to low metastatic 
variants (Fl) through fusion with membrane 
vesicles from FlO [l]. Similarly, several surface 
parameters of metastatic tumour cells such as 
sialylation of surface components, lectin binding, 
and presence of surface proteases, have been ex- 
plored, and a correlation with the metastatic 
potential has often been observed (see [2-41). 
A promising approach to the identification of 
surface components involved in cell adhesion is the 
production of antibodies, either polyclonal or 
monoclonal, which inhibit cell-cell or cell- 
substrate interactions (5-81. We have recently 
generated a series of mono~lonat antibodies 
against B16 mouse melanoma cells by immunizing 
syngeneic C57BIJ6 mice and fusion of the 
splenocytes with NS-1 myeIoma cells. The selected 
antibodies inhibit the in vitro adhesion of B16 
melanoma cells and react with various other 
murine and human tumour and embryonal ceil 
lines but not with untransformed cells [8,9]. in 
vivo, three of the antibodies (16/43, 16/77, 16182) 
prevented lung colonization of highly metastatic 
B16 melanoma cells [S]. To examine with which 
step of the metastatic cascade these antibodies 
might interfere in vivo, we studied their effect on 
various cellular and acellular surfaces in vitro. 
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2. EXPERIMENTAL 3. RESULTS 
B16 subclones of different metastatic potential 
were produced by limiting dilution and were tested 
by intravenous injection (2 x 16 cells per 
C57BL/6 mousef as in [S]. For description of the 
human tumour cell lines see [9]. 
2.2. Adhesion assay 
Bacterial plastic dishes were coated at room 
temperature for 2 h with laminin (15 pug/ml), 
fibronectin (5 pg/ml), or collagen IV (5 pg/ml) in 
phosphate-buffered saline. Human fibronectin 
was prepared as in [lo], laminin and collagen IV 
were generous gifts from Dr R. Timpl (Munich). 
~ndotheliai cells from bovine aorta were seeded at 
1000 cells/well on Terasaki plates and were allow- 
ed to reach confluency [I I]. Trypsinized B16 
mouse meianoma and human tumour cells (400 
cells/50pl for coated plastic dishes and 200 
cells/20 ~1 for endothelial monolayers) were plated 
in hybridoma snpernatants (vs control medium) 
for 30 min at 37°C and attached cells were counted 
as in [8,11], 
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Fig.1. Time course for cell adhesion to the various 
substrata. Bacterial plastic dishes and Terasaki plates 
were coated with laminin (0). fibron~tin (A), collagen 
(0) and bovine aortic endothefial celIs (A) as described 
in section 2. Trypsinized B16 cells were plated and 
incubated at 37°C. Attached cells were counted at 
different times. 
B16 melanoma cells in the presence or absence 
of antibodies were seeded: (i) on bacterial plastic 
dishes coated with components of the basal lamina 
such as laminin, fibronectin or collagen IV; or (ii) 
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Fig.2, Effect of monoclonal antibodies on the adhesion 
of B16 melanoma cells to cellular and acellular surfaces. 
Trypsinized B16 melanoma cells of different metastatic 
potential were plated in hybridoma supernatants (vs 
NS-1 contro1 medium) on different substrates, and 
attached cells at various times were counted as in [8,1 I]. 
Inhibition of adhesion produced by the 3 antibodies 
(average data from 2 different experiments) are 
expressed in bars (s70 inhibition in comparison to NS-I 
control medium) as indicated by the hatched area 
(antibody 16/43), black area (antibody 16/77), and 
dotted area (antibody 16/82). The different B16 
melanoma lines are: (a) clone 129 (340 lung metastases 
in C57BL/6 mice); (b) clone 139 (164 lung metastases); 
(c) clone 164 (40 lung metastases); (d) FIO (50 Iung 
metastases); (e) FL (5 lung metastases); (f) clone 56 (no 
metastases). Metastasis formation was analysed by 
intravenous injection of 2 x lo5 celh into mice as in [8]. 
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on confluent monolayers of aortic endothelial cells 
grown in tissue culture. B16 melanoma cells at- 
tached to all substrates within 30 min (fig.1). 
Examination of the 3 antibodies revealed that 
they were highly active in preventing the adhesion 
of melanoma cells to laminin (fig.2). In general, in- 
hibition of 30-90% was observed on laminin, 
whereas the corresponding values on fibronectin 
and collagen IV were between O-25%. The an- 
tibodies were virtually inactive when B16 cells 
adhered to aortic endothelial monolayers (fig.2) or 
to extracellular matrix of cornea1 endothelial cells 
(not shown). We have also compared the effec- 
tiveness of the antibodies on B16 sublines of dif- 
ferent metastatic potential. In all cases the inhibi- 
tion was most effective on laminin (fig.2), thus no 
clear correlation was found between metastatic 
potential of the cells and the activity of the an- 
tibodies. High activity of the antibodies on laminin 
substrate was also found with different human 
tumour cell lines (fig.3). 
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Fig.3. Effect of monoclonal antibodies on the adhesion 
of human tumour cells to cellular and acellular surfaces. 
Experiments were performed as described in the legend 
to fig.2. The cells were: (a) TR126, a freshly isolated 
tongue carcinoma cell line; (b) TuWi, from Wilm 
turnout-; (c) Tagli, a freshly isolated glioblastoma cell 
line (see [9]). 
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4. DISCUSSION 
The finding that monoclonal antibodies can 
reduce experimental lung lesions in mice and also 
reduce the adhesion of tumour cells to laminin has 
implications for our understanding of the process 
of metastasis and the mechanism of interference by 
antibodies. The formation of blood-borne 
metastases falls into several distinct steps: cir- 
culating tumour cells must adhere to the en- 
dothelial surfaces of the target organs, they then 
seem to induce endothelial cells to retract, and they 
must finally break through the underlying base- 
ment membrane (which contains laminin) and 
enter mesenchymal tissue [3,4]. Thus, metastatic 
tumour cells are able to adhere both to other cells 
(cell-cell interaction) and to acellular components 
of the basement membrane (cell-substrate interac- 
tion). It is clear from previous studies that dif- 
ferent cellular mechanisms and also different cell 
surface molecules are responsible for these two 
types of interactions [5-9,121. As judged from the 
presented ata, our monoclonal antibodies seem to 
interfere with a kind of cell-substrate interaction; 
the antibodies were initially selected for such an ac- 
tivity (on tissue culture plates, [S]), and they have 
now been shown to be highly active on laminin 
substrates. Anti-B16 antibodies which did not in- 
hibit or only moderately affected metastasis for- 
mation in C57BL/6 mice [S] showed a more com- 
plex inhibition pattern in vitro. For instance, an- 
tibody 19/l (in vivo negative) inhibits attachment 
on laminin as well as on collagen IV, whereas an- 
tibodies 16/51 and 16/56 (in vivo slightly positive) 
also specifically blocked adhesion to laminin, but 
to a lower degree (only 15-40% with clones 129 
and 139). This suggests that the interaction bet- 
ween metastatic tumour cells and a laminin- 
containing substrate, e.g., in the vascular en- 
dothelial basement membrane, might be important 
at one point of metastasis. 
Several laboratories have recently shown that 
various tumour and non-tumour cells express 
laminin receptors on their surfaces [ 13-151; these 
receptors have M, values of 60-70000 on SDS- 
polyacrylamide gel electrophoresis. However, our 
antibodies react with components of M, 40-50000 
[9]. Thus, it is likely that they interfere with adhe- 
sion through a surface component different from 
the commonly recognized laminin receptor. Alter- 
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natively, the antibodies might prevent adhesion of 
metastatic tumour cells to laminin by indirect 
signaling mechanisms (for a discussion of these 
possibilities see 171). Interestingly, no difference 
between high and low metastatic B16 variants in 
their adhesion to laminin and in the antibody ef- 
fects in vitro could be seen (fig.2, for a discussion 
of the properties of such variants see [2,3]). This 
indicates that the binding of the tumour cells to 
Iaminin-containing structures in vivo is surely but 
one step in metastasis formation. However, as 
others have suggested as well [ 161, it seems to be 
one with a great potential for anti-metastatic 
therapy. 
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